FDA Warning Letter
#Formal written notice from the FDA that a practice or company is violating FDA rules and must correct the violations within a stated timeframe.
The 29+ terms that show up in FDA warning letters, FTC actions, and state board discipline - in plain English.
The FDA regulates what you can claim a treatment does. Wrong claim category = warning letter.
Formal written notice from the FDA that a practice or company is violating FDA rules and must correct the violations within a stated timeframe.
A marketing statement about how a product affects the structure or function of the body without claiming to treat, cure, or prevent a specific disease.
A marketing statement claiming that a product can diagnose, treat, cure, prevent, or mitigate a specific disease.
A claim that doesn't directly say 'treats disease' but conveys the same meaning through context, testimonials, or associated content.
Key takeaway
If you claim a product treats, cures, or prevents a condition, you are making a disease claim - which legally turns the product into a drug requiring FDA approval before you can market it.
A court-enforced settlement between a regulator and a defendant, establishing binding corrective measures and ongoing oversight.
An FDA enforcement communication for violations that are less serious than warning letters but still require correction.
Related
Written observations issued by FDA investigators during inspections, noting specific practices that may violate FDA regulations.
A drug, device, or tissue product that fails to meet FDA safety, purity, manufacturing, or quality standards.
A drug, device, or tissue product whose labeling (including advertising) is false, misleading, or omits required information.
The FDA center that regulates biological products - including vaccines, blood products, gene therapies, and human cell and tissue products (HCT/Ps).
Key takeaway
Warning letters, untitled letters, and Form 483s all start the same way: a regulator notices marketing language that misbrands or adulterates a product. The fastest fix is fixing the words on the page.
Human Cells, Tissues, and Cellular and Tissue-Based Products - the FDA regulatory category that includes stem cells, bone marrow concentrate, amniotic tissue, and related products.
Promotional marketing of an FDA-approved drug or device for uses that are not part of its FDA-approved labeling.
The statutory definition of a 'drug' under the Federal Food, Drug, and Cosmetic Act - which is triggered by the claims made about a product.
FDA authorization allowing an experimental drug to be used in clinical trials before approval.
One of the criteria HCT/P products must meet to fall under the 361 pathway without FDA premarket approval.
Key takeaway
For HCT/P-based regen practices, the 361 pathway depends on minimal manipulation and homologous use. Marketing that describes advanced processing or non-native uses can quietly push the product into the 351 (drug) pathway.
One of the criteria HCT/P products must meet to fall under the 361 pathway - the product must perform the same basic function it performed in the donor.
The federal law establishing the regulatory framework for dietary supplements - including what claims supplements can and cannot make.
The FTC governs how you advertise - testimonials, endorsements, and disclosures must hold up under deception review.
Any relationship between an endorser and a marketer that would affect the weight or credibility of the endorsement - and which must be clearly disclosed.
Required disclosure accompanying any endorsement or testimonial describing experience or results that aren't generally typical of what users would experience.
Federal rules governing the use of endorsements, testimonials, influencer partnerships, and reviews in advertising - including disclosure, substantiation, and typical-experience requirements.
The evidence required to support every objective claim made in advertising.
Key takeaway
Any compensated, gifted, or even loaned-product relationship between you and an endorser must be disclosed clearly and conspicuously - and any testimonial that does not reflect typical results needs a typical-experience disclosure.
The FTC standard for how prominently disclosures must be presented - including size, color, placement, and duration.
The FTC's substantiation standard - tests, analyses, research, or studies conducted and evaluated objectively by qualified people using generally-accepted procedures.
The primary category of FTC enforcement - any material representation, omission, or practice likely to mislead reasonable consumers.
Cleared and approved are not the same thing. Mixing the two on a device page is the fastest aesthetic-industry warning letter.
A premarket notification pathway allowing a medical device to be marketed based on substantial equivalence to an existing legally-marketed device.
Two different FDA pathways with different evidentiary standards - and legally distinct statuses that must not be conflated in marketing.
Related
State medical boards can suspend a license faster than the FDA can finish a warning letter. Their advertising rules are often stricter than federal.
State-level rules governing physician and practice advertising, specialty claims, supervision requirements, and professional conduct.
Related
Cross-cutting rules - HIPAA marketing, cease-and-desist letters, and the legal mechanics that touch every other category.
RegenCompliance applies every rule in this glossary automatically to every piece of content you scan. 30 seconds, not a law degree.